Orrick has advised San Francisco-based synthetic biology company Twist Bioscience (NASDAQ: TWST) on its upsized underwritten public offering of 5,227,272 shares of its common stock at a public offering price of $55 per share, including the exercise in full by the underwriters of their option to purchase up to an additional 681,818 shares of common stock in the offering. Twist estimates net proceeds from the offering to be approximately $269.4 million. Twist intends to use the net proceeds of the offering to scale its investment in its research and development organization.
J. P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and William Blair & Company, L.L.C. acted as joint book-running managers.